Long-term Maintenance of Remission with No Dose Escalation Aft er Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation: 3-year Results from the PRECiSE 4 Study

被引：0
|
作者：
Sandborn, William [1 ]
Schreiber, Stefan [2 ]
Hanauer, Stephen [3 ]
Colombel, Jean-Frederick [4 ]
Bloomfield, Ralph [5 ]
Lichtenstein, Gary [6 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Univ Kiel, Kiel, Germany
[3] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[4] Hop Claude Huriez, Lille, France
[5] UCB Pharma, Slough, Berks, England
[6] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2009年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1207
引用
收藏
页码：S448 / S448
页数：1
相关论文
共 50 条
  • [21] Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study
    Lee, Scott D.
    Rubin, David T.
    Sandborn, William J.
    Randall, Charles
    Younes, Ziad
    Schreiber, Stefan
    Schwartz, David A.
    Burakoff, Robert
    Binion, David
    Dassopoulos, Themos
    Arsenescu, Razvan
    Gutierrez, Alexandra
    Scherl, Ellen
    Kayhan, Cem
    Hasan, Iram
    Kosutic, Gordana
    Spearman, Marshall
    Sen, David
    Coarse, Jason
    Hanauer, Stephen
    [J]. INFLAMMATORY BOWEL DISEASES, 2016, 22 (08) : 1870 - 1880
  • [22] Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study
    Sandborn, William J.
    Schreiber, Stefan
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Bloomfield, Ralph
    Lichtenstein, Gary R.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 696 - 702
  • [23] Long-Term Remission With Certolizumab Pegol in Crohn's Disease: Efficacy Over 4 Years in Patients With NO Prior TNF-α Inhibitor Exposure (PRECiSE 3 Study)
    Lichtenstein, Gary
    Thomsen, Ole O.
    Schreiber, Stefan
    Lawrance, Ian C.
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S165 - S165
  • [24] Patients With Crohn's Disease Treated With Certolizumab Pegol Experienced Long-Term Remission Regardless of Prior TNF-α Inhibitor Exposure (PRECiSE 4 Study)
    Sandborn, William J.
    Schreiber, Stefan
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Bloomfield, Ralph
    Lichtenstein, Gary
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S9 - S9
  • [25] Long-term treatment with certolizumab pegol for up to 18 months in patients with active Crohn's disease: Precise 3 efficacy results
    Schreiber, Stefan
    Hanauer, Stephen B.
    Feagan, Brian G.
    Bloomfield, Ralph
    Rutgeerts, Paul
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A504 - A504
  • [26] Long-term remission with certolizumab pegol in Crohn's disease: Efficacy over 4.5 years in patients with no prior TNF inhibitor exposure (PRECiSE 3 study).
    Lichtenstein, G.
    Thomsen, O.
    Schreiber, S.
    Lawrance, I
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S51 - S52
  • [27] Long-term Remission with Certolizumab Pegol in Crohn's Disease: Efficacy Over 4.5 Years in Patients with No Prior TNF Inhibitor Exposure (PRECiSE 3 Study)
    Lichtenstein, Gary
    Thomsen, Ole
    Schreiber, Stefan
    Lawrance, Ian
    Hanauer, Stephen
    Bloomfield, Ralph
    Sandborn, William
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S417 - S418
  • [28] Improvement in Quality of Life as a Predictor of Long-Term Remission in Crohn's Disease Patients Treated with Certolizumab Pegol
    Feagan, Brian
    Schreiber, Stefan
    Spearman, Marshall
    Kosutic, Gordana
    Hasan, Iram
    Coarse, Jason
    Sandborn, William
    [J]. INFLAMMATORY BOWEL DISEASES, 2016, 22 : S41 - S41
  • [29] Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol
    Melmed, Gil Y.
    McGovern, Dermot
    Schreiber, Stefan
    Kosutic, Gordana
    Spearman, Marshall
    Coarse, Jason
    Sandborn, William J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (12) : 1937 - 1941
  • [30] Disease Activity as a Predictor of Long-Term Outcomes of Treatment With Certolizumab Pegol for Active Crohn's Disease: An Analysis of the PRECiSE 3 Study
    Choi, Jennifer
    Abraham, Bincy
    Wolf, Douglas
    Colombel, Jean-Frederic
    Kosutic, Gordana
    Spearman, Marshall
    Coarse, Jason
    Sandborn, William
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S509 - S510
12345